MDxHealth SA (NASDAQ:MDXH) Given Average Rating of “Moderate Buy” by Brokerages

MDxHealth SA (NASDAQ:MDXH) has been given an average recommendation of “Moderate Buy” by the six ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $4.6250.

MDXH has been the subject of a number of analyst reports. Lake Street Capital decreased their price objective on shares of MDxHealth from $9.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, May 14th. William Blair cut shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. TD Cowen reissued a “buy” rating and issued a $1.50 price objective (down from $7.00) on shares of MDxHealth in a research report on Thursday, May 14th. Wall Street Zen cut MDxHealth from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of MDxHealth in a research note on Friday, March 27th.

Hedge Funds Weigh In On MDxHealth

Several institutional investors and hedge funds have recently made changes to their positions in MDXH. Intesa Sanpaolo Wealth Management purchased a new position in shares of MDxHealth during the 4th quarter valued at approximately $36,000. Lido Advisors LLC bought a new position in shares of MDxHealth during the third quarter worth about $48,000. GSA Capital Partners LLP bought a new position in shares of MDxHealth during the third quarter worth about $48,000. Squarepoint Ops LLC bought a new position in shares of MDxHealth during the fourth quarter worth about $51,000. Finally, Jefferies Financial Group Inc. bought a new position in shares of MDxHealth during the third quarter worth about $53,000.

MDxHealth Stock Down 0.9%

NASDAQ MDXH opened at $0.75 on Monday. The stock has a market cap of $37.27 million, a PE ratio of -1.16 and a beta of 1.37. MDxHealth has a fifty-two week low of $0.68 and a fifty-two week high of $5.33. The business has a 50 day moving average price of $1.92 and a two-hundred day moving average price of $2.94.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The firm had revenue of $23.90 million during the quarter, compared to analysts’ expectations of $30.89 million. MDxHealth had a negative net margin of 29.90% and a negative return on equity of 1,078.01%. Sell-side analysts anticipate that MDxHealth will post -0.6 EPS for the current fiscal year.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.